Infantile Spasms Therapeutics Market will expand at 3.6% CAGR to hit 170 million US$ by 2025: QY Research, Inc.

QY Research has come up with a newly published report on global Infantile Spasms Therapeutics market in its database that provides an in-depth analysis of the key market insights, its future trends, and developments, profiles of leading players, key restraints and drivers, segmentation and forecasting. The report highlights the Infantile Spasms Therapeutics market size and CAGR of the important segments, thus providing quick relevant information about the global Infantile Spasms Therapeutics market.

The global Infantile Spasms Therapeutics market is valued at 130 million US$ in 2018 is expected to reach 170 million US$ by the end of 2025, growing at a CAGR of 3.6% during 2019-2025.

Get PDF template of this report: https://www.qyresearch.com/sample-form/form/960222/global-infantile-spasms-therapeutics-industry-analysis-report

An infantile spasm (IS), also known as West Syndrome, is a specific type of seizure seen in an epilepsy syndrome of infancy and childhood. West Syndrome is characterized by infantile spasms, developmental regression, and a specific pattern on electroencephalography (EEG) testing called hypsarrhythmia (chaotic brain waves). The onset of infantile spasms is usually in the first year of life, typically between 4-8 months. The seizures primarily consist of a sudden bending forward of the body with stiffening of the arms and legs; some children arch their backs as they extend their arms and legs. The condition is usually observed in 2% of childhood epilepsies and 25% of epilepsies that start in the first year of life.
The global infantile spasms therapeutics market is growing at a slow pace. This is due to the increased availability of generic drugs and less approved therapies in the market and the less awareness of the disease and the available treatment options, especially in the low- and middle-income countries.

The classification of Infantile Spasms Therapeutics includes Oral, Injection. The proportion of Injection in 2016 is about 45%, and the proportion of Oral in 2016 is about 55%.

Based on application, the nitinol medical devices market is segmented into Hospital, Clinic and others. Clinic segment accounted for larger market share in terms of sales in 2016, Clinic segmented accounted for more than 45% of the market share in 2016.

The United States is the largest consumption place, with a consumption market share nearly 83% in 2016. Following the United States, Europe is the second largest consumption place with the consumer market share of 12.6% in 2016.

The US market is dominated by two approved products H.P. Acthar Gel (adrenocorticotropin hormone) and Sabril (vigabatrin). Sabril was the first drug to be approved by the Food and Drug Administration (FDA) in 2009 and H.P. Acthar Gel (adrenocorticotropin hormone) was approved for infantile spasms in 2010. Both have Orphan Drug Exclusivity (ODE) in the US.
In the future, the Infantile Spasms Therapeutics will have a good future; the price fluctuation has relationship with the raw material. The technology will more mature and the industry is more dispersion.

Major Key Manufacturers of Infantile Spasms Therapeutics Market are:

Mallinckrodt
H. Lundbeck
Insys Therapeutics
Orphelia Pharma
Valerion Therapeutics
Catalyst Pharmaceuticals
Anavex Life Sciences
Retrophin
GW Pharmaceuticals

Infantile Spasms Therapeutics market includes market size, segmentation data and geographical analysis of market growth trends, leading companies, and microeconomic information.

Major Classification as follows:

Oral
Injection

Major Application as follows:

Hospital
Clinic

Get Complete Report in your Inbox within 24 hours: https://www.qyresearch.com/settlement/pre/564f238754c96540f07b9e8495be10ab,0,1,Global%20Infantile%20Spasms%20Therapeutics%20Industry%20Analysis%20Report%202019

Reasons to buy this report:

The Infantile Spasms Therapeutics report is designed in a method that assists clients to acquire a complete knowledge of the overall market scenario and the important sectors.

This report consists of a detailed overview of Infantile Spasms Therapeutics market dynamics and comprehensive research.

Explore further Infantile Spasms Therapeutics market opportunities and identify high potential categories based on detailed volume and value analysis.

Detail information on competitive landscape, Infantile Spasms Therapeutics recent market trends and changing technologies that can be useful for the companies which are competing in the Infantile Spasms Therapeutics industry.

Gaining knowledge about Infantile Spasms Therapeutics market competitive landscape based on detailed brand share analysis to plan an effective market positioning.

About Us:

QYResearch always pursuits high product quality with the belief that quality is the soul of business. Through years of effort and supports from the huge number of customer supports, QYResearch consulting group has accumulated creative design methods on many high-quality markets investigation and research team with rich experience. Today, QYResearch has become the brand of quality assurance in the consulting industry.

Contact

Rutuja Karwa
QY Research, INC.
USA: +1 6262 952 442
China: +86 1082 945 717
Japan: +81 9038 009 273
India: +91 9766 478
Emails – enquiry@qyresearch.com
Web – www.qyresearch.com

This release was published on openPR.